人类血清α-klotho度的预后值在心力衰竭患者中,心力衰竭患者的预后值减少了喷射分数
Ajay Mahenthiran1, Silvio Augusto Nunes2, Chia-Feng Liu2
1Case Western Reserve University, Cleveland, OH, United States.
Clinical biochemistry
|January 21, 2026
概括
较高的血清α-klotho水平与心力衰竭 (HF) 患者的更好的生存率和较低的NT-proBNP有关. 这表明alpha-klotho是HF风险分层的一个有希望的生物标志物.
科学领域:
- 心脏病学 心脏病学
- 生物标志物发现发现
- 老年学是指老年学的学科.
背景情况:
- 心脏衰竭 (HF) 是一个重大的全球健康挑战,死亡率高.
- 识别新的生物标志物对于管理HF进展至关重要.
- 血清α-klotho在HF结果中的作用需要进一步调查.
研究的目的:
- 评估血清α-klotho度与稳定心力衰竭 (HF) 患者的长期全因死亡率之间的关联.
- 探索α-klotho作为HF风险分层的潜在生物标志物.
主要方法:
- 血清α-klotho水平测量了230名成年人 (135名HF患者,95名对照).
- 分类和回归树分析根据α-klotho水平对患者进行了分层.
- 卡普兰-梅尔生存分析评估了5年全因死亡率.
- 克鲁斯卡尔-瓦利斯试验在不同组中比较了log-NT-proBNP水平.
主要成果:
- 较高的血清α-klotho度与明显较低的全因死亡率相关.
- 患有较高α-klotho的患者表现出较低的log-NT-proBNP水平.
- 卡普兰-梅尔分析显示,与较高的α-klotho水平相关的显著生存益处 (逻辑等级p < 0.01).
结论:
- 血清α-klotho升高与HF患者的死亡率降低和NT-proBNP降低有关.
- α-klotho 可能作为一种有价值的心脏保护生物标志物,用于心力衰竭的风险分层.
- 这些发现突显了α-klotho在改善高温管理策略方面的潜力.
相关概念视频
01:29Heart Failure II: Pathophysiology
790
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
790
01:17Pathophysiology of Heart Failure
3.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
01:27Heart Failure I: Introduction
729
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
729
01:22Heart Failure VI: Adjunct Therapies
278
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
278
01:22Heart Failure Drugs: Diuretics
825
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
825
01:30Heart Failure V: Medical Management
227
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
227